Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bepirovirsen on Cardiac Conduction in Healthy Volunteers
NCT06422767Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2024
- Primary completion
- Apr 2025
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bepirovirsen in hepatitis B (HBV) (4 arms), sponsored by GSK. Primary endpoint: Placebo-corrected Change From Baseline in QT Interval Corrected by Fridericia's Formula at Day 4. Started Jul 2024; status: completed.
02
Drugs
bepirovirsen
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT06422767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422767.